ArticleCytotechnology2026
SDC4 silencing promotes cell cycle arrest at the restriction point (R point) in anoikis-resistant endothelial cells.
Article in Cytotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many tumor cells exhibit resistance to anoikis, facilitating their invasion and contributing to tumor metastasis. Previous studies have shown that anoikis-resistant endothelial cells overexpress syndecan-4 (SDC4), a co-receptor for growth factors that interacts with extracellular matrix (ECM) proteins. While SDC4 is well-known for its role in cellular processes such as adhesion, migration, and proliferation, its specific involvement in cell cycle dysregulation in tumor cells remains poorly understood. This study aimed to investigate the role of SDC4 in regulating the cell cycle in anoikis-resistant endothelial cells. Methods included the use of wild-type endothelial cells (EC), EJ-ras oncogene-transfected EC (EJ-ras EC), anoikis-resistant EC (Adh1-EC), and SDC4-silenced EC (miR-Syn-4-1-Adh-EC). Gene and protein expression of regulatory molecules across different phases of the cell cycle were analyzed using qPCR, western blotting, and flow cytometry. The Integrated Biomarker Response (IBR) index was employed to interpret cellular responses, and cell viability was assessed after adhesion blockade. Results showed that while cyclin D1 was highly expressed in the G1 phase, SDC4-silenced cells exhibited increased p27 expression, which impairs the activity of the cyclin E-CDK2 complex, suggesting a potential hindrance to cell cycle progression. Additionally, a reduction in cyclin B1 expression was observed. The IBR index for cyclins and CDKs was 2.19 and 3.24, respectively, following Supplementary Information: The online version contains supplementary material available at 10.1007/s10616-026-00931-x.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.